Key result
This review summarizes the pathophysiological mechanisms by which type 2 diabetes mellitus promotes heart failure with preserved ejection fraction and discusses potential pharmacological treatments.
Why the study?
Type 2 diabetes mellitus increases the risk of heart failure with preserved ejection fraction and worsens symptoms, yet no specific treatment has been shown to reduce morbidity and mortality in these patients.
This review summarizes the pathophysiology and potential pharmacological treatments for patients with concurrent HFpEF and type 2 diabetes mellitus.
Type 2 diabetes mellitus is known to increase the risk of the development of heart failure with preserved ejection fraction and worsen its symptoms. To date, no specific treatment has been shown to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction. In this review, the authors summarized the existing evidence on how diabetes mellitus can promote the development and progression of heart failure with preserved ejection fraction. The authors also addressed medications including experimental ones that can potentially be beneficial in patients of this group.
No takes yet. Share an insight, caveat, or question.
Aa et al. (2021) conducted a review in Heart failure with preserved ejection fraction and type 2 diabetes mellitus. Heart failure medications was evaluated. This review summarizes the pathophysiological mechanisms by which type 2 diabetes mellitus promotes heart failure with preserved ejection fraction and discusses potential pharmacological treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Heart failureMore from Medical Herald of the South of Russia